esperion | Esperion Home | Esperion Therapeutics, Inc.

Keyword	CPC	PCC	Volume	Score	Length of keyword
esperion	1.72	0.9	2088	52	8

Keyword	CPC	PCC	Volume	Score
esperion	0.58	0.1	1998	15
esperion therapeutics	0.73	0.4	7352	35
esperion stock	0.93	0.6	8766	91
esperion fc	0.46	0.6	5287	16
esperion pharmaceuticals	1.95	0.1	638	55
experian credit	1.8	0.3	9519	20
esperion careers	0.95	0.1	7689	14
esperion therapeutics stock	0.46	0.1	2213	87
esperion yahoo	1	0.5	4741	64
esperion stock price	1.67	0.6	8321	41
esperion therapeutics news	0.5	0.9	7123	26
esperion yahoo finance	1.42	0.8	4775	51
esperion therapeutics stock price	0.23	0.7	4136	93
esperion theraps inc	0.21	0.6	5524	35
esperion team logo	1.73	0.9	6360	78
esperion news	1.93	0.4	5423	54
experian credit report	1.25	0.6	8898	5
esperion patient assistance program	1.04	0.2	8982	40

Search Results related to esperion on Search Engine

Esperion Home | Esperion Therapeutics, Inc.
esperion.com

https://www.esperion.com/

WEBLearn More. Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.

DA: 78 PA: 84 MOZ Rank: 80

Esperion Therapeutics, Inc. (ESPR) - Yahoo Finance
yahoo.com

https://finance.yahoo.com/quote/ESPR

WEBFind the latest Esperion Therapeutics, Inc. (ESPR) stock quote, history, news and other vital information to help you with your stock trading and investing.

DA: 1 PA: 72 MOZ Rank: 38

U.S. FDA Approves Broad New Labels for NEXLETOL® and ... - esperion…
esperion.com

https://www.esperion.com/news-releases/news-release-details/us-fda-approves-broad-new-labels-nexletolr-and-nexlizetr-prevent

WEBMar 22, 2024 · U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use | Esperion Therapeutics, Inc. Press Release.

DA: 57 PA: 37 MOZ Rank: 90

Investors and Media | Esperion Therapeutics, Inc.
esperion.com

https://www.esperion.com/investors-media

WEBApr 1, 2024 · Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity. Apr 01, 2024. Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024. View All News.

DA: 36 PA: 80 MOZ Rank: 99

Esperion Therapeutics - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Esperion_Therapeutics

WEBEsperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor , Michigan.

DA: 48 PA: 40 MOZ Rank: 41

Pipeline | Esperion Therapeutics, Inc.
esperion.com

https://www.esperion.com/science/pipeline

WEBAlong with the implementation of leading-edge discovery technology and data science approaches, Esperion aims to reveal new therapeutic opportunities and develop next-generation inhibitors optimized to address multiple life-threatening diseases.

DA: 17 PA: 61 MOZ Rank: 1

Careers | Esperion Therapeutics, Inc.
esperion.com

https://www.esperion.com/careers

WEBCollaboration. We are a high-performing team that leverages our diversity and resources by partnering across business functions to build a supportive environment where we can achieve our goals. Integrity. We are committed to honesty, quality, and transparency. We build trust by doing the right thing.

DA: 56 PA: 84 MOZ Rank: 7

When Is Your Next Cholesterol Test? | Esperion Therapeutics, Inc.
esperion.com

https://www.esperion.com/our-company/about-us

WEBProviders are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work.

DA: 44 PA: 38 MOZ Rank: 62

Esperion Announces CLEAR Cardiovascular Outcomes Trial of …
esperion.com

https://www.esperion.com/news-releases/news-release-details/esperion-announces-clear-cardiovascular-outcomes-trial-nexletolr

WEBANN ARBOR, Mich., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial met its primary endpoint, demonstrating statistically significant risk reduction in MACE-4 in patients treated with 180 mg/day …

DA: 51 PA: 51 MOZ Rank: 17

Esperion Therapeutics Inc (ESPR) Stock Price & News - Google
google.com

https://www.google.com/finance/quote/ESPR:NASDAQ

WEBEsperion Therapeutics Inc. $1.95. After Hours: $1.94. (0.51%) -0.0100. Closed: Apr 19, 8:00:00 PM GMT-4 · USD · NASDAQ · Disclaimer. 1D. 5D. 1M. 6M. YTD. 1Y. 5Y. MAX. search Compare to. Tilray...

DA: 92 PA: 19 MOZ Rank: 34